Key result
Cardiomyocytes act as immunoactive units in diabetic cardiomyopathy, participating in early hyperglycemia-triggered inflammation.
Why the study?
Optimal glycemic control does not prevent diabetic cardiomyopathy, prompting a focus on the role of cardiomyocytes as active immunoactive units driving early inflammatory perturbation.
Design
Review
Authors
Loading...
Cardiomyocyte inflammation should not yet guide therapy in diabetic cardiomyopathy; leaves open validation of these targets in prospective trials.
Cardiomyocytes play an active role in the inflammatory and metabolic processes underlying diabetic cardiomyopathy, suggesting early inflammatory mediators as potential therapeutic targets.
Filardi et al. (2019) conducted a review in Diabetic cardiomyopathy. Cardiomyocytes act as active immunoactive units in diabetic cardiomyopathy, participating in early inflammatory processes triggered by hyperglycemia that represent potential therapeutic targets.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: